敏实(00425.HK)附属与海拉控股成立雷达罩相关业务合资
敏实集团(00425.HK)公布,公司一间全资附属敏实投资已於昨日(17日)与汽车零部件供应商海拉控股订立框架协议及合资合同,通过成立雷达罩相关业务之合资公司,以及订立关於合资公司成立及管理之条款,使合资双方形成战略联盟。
合资双方计划成立合资公司以设计、开发、生产、测试及销售汽车零部件,注册资本将为1.44亿元人民币,主要为雷达罩及发光标识。敏实投资将首先成立中国外商独资企业,向其注入注册资本,并促使中国外商独资企业收购目标资产。於中国外商独资企业完成对目标资产的收购及满足框架协议所规定的其他条件後,海拉控股将向中国外商独资企业注入注册资本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.